Pregabalin Confers No Added Benefit to a Non-steroid Anti-inflammatory Drug and Acetaminophen Regimen in Outpatient Breast Cancer Surgery: A Randomized Controlled Trial
- *Corresponding Author:
- Ronald B. George
IWK Health Centre, Department of Women’s & Obstetric Anesthesia
5850/5980 University Avenue, P.O. Box 9700, Halifax
NS, B3K 6R8, Canada, B3K 6R8
Tel: (902) 470-6627
Fax: (902) 470-6626
E-mail: [email protected]
Received date: January 20, 2014; Accepted date: February 17, 2014; Published date: February 19, 2014
Citation: George RB, McKeen DM, Boyd JC, Porter GA (2014) Pregabalin Confers No Added Benefit to a Non-steroid Anti-inflammatory Drug and Acetaminophen Regimen in Outpatient Breast Cancer Surgery: A Randomized Controlled Trial. J Anesth Clin Res 5:383. doi: 10.4172/2155-6148.1000381
Copyright: © 2014 George, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objectives: Multimodal analgesia may reduce both postoperative pain and the risk of adverse effects associated with opioid-use. Pregabalin has emerged as a potential perioperative analgesic with an improved pharmacokinetic profile. However, data regarding its analgesic efficacy and optimal dose following breast surgeries are conflicting. This study was designed to determine if perioperative treatment with pregabalin could reduce pain scores and oxycodone consumption following elective surgery for possible breast cancer.
Methods: Fifty-nine women undergoing elective breast cancer surgery (mastectomies and lumpectomies) were recruited for this study. Patients were randomized to pregabalin (150 mg) or placebo, both administered prior to surgery and 12 hours postoperatively. Pain and nausea intensity were measured using an 11-point numerical rating scale 2, 24, and 48 h postoperatively. Acetaminophen, naprosyn, and oxycodone were available in both groups postoperatively.
Results: At 24 hours post-op there were no differences in average pain intensity at rest (placebo 1.3 vspregabalin 0.6; difference=0.65, 95% CI: -0.09 to 1.39, p=0.08), pain following movement (placebo 1.3 vs P150 1.2; difference=0.14, 95% CI: -0.59 to 0.88, p=0.70, or average oxycodone tablet consumption (placebo 0.7 vs P150 1.0, difference=0.26, 95% CI: -1.86 to 1.35, p=0.72) postoperatively.
Conclusion: Pregabalin given preoperatively and 12 h postoperatively did not improve pain or oxycodone consumption 24 h following breast surgery. Further research regarding the appropriate dose and timing of pregabalin administration surrounding breast surgery is required.